JAK inhibitors to treat STAT3 gain-of-function: a single-center report and literature review

ObjectiveThe signal transducer and activator of transcription 3 (STAT3) gain-of-function (GOF) syndrome (STAT3-GOF) is an inborn error of immunity (IEI) characterized by diverse manifestations of immune dysregulation that necessitate systemic immunomodulatory treatment. The blockade of the interleuk...

Full description

Bibliographic Details

Published in:	Frontiers in Immunology
Main Authors:	Faranaz Atschekzei, Stephan Traidl, Julia Carlens, Katharina Schütz, Sandra von Hardenberg, Abdulwahab Elsayed, Diana Ernst, Linus Risser, Thea Thiele, Theresa Graalmann, Juliana Raab, Ulrich Baumann, Torsten Witte, Georgios Sogkas
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-08-01
Subjects:	STAT3 gain-of-function JAK inhibitors baricitinib ruxolitinib tofacitinib arthritis
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1400348/full